Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • nasopharyngeal cancer

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    EU flag

    CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

    Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    EU flag

    EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1

    Neurofibromatosis type 1 affects an estimated 135,000 people in the EU

    - PMLiVE

    NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

    Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

    EU flag

    EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

    The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    - PMLiVE

    AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer

    More than 35,000 people in five major European countries were treated for the disease last year

    - PMLiVE

    Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval

    The rare inherited disease affects more than 109,000 people worldwide

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links